These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10558310)

  • 1. The gynecological Pap test.
    Rinas AC
    Clin Lab Sci; 1999; 12(4):239-45. PubMed ID: 10558310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Pap test abnormalities within 3 years of a normal Pap test--United States, 1991-1998.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Nov; 49(44):1001-3. PubMed ID: 11097139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the Centers for Disease Control and Prevention. Incidence of Pap test abnormalities within 3 years of a normal Pap test--United States, 1991-1998.
    JAMA; 2000 Dec; 284(21):2714-5. PubMed ID: 11187126
    [No Abstract]   [Full Text] [Related]  

  • 4. Unindicated cervical cancer screening in adolescent females within a large healthcare system in the United States.
    Hosier H; Sheth SS; Oliveira CR; Perley LE; Vash-Margita A
    Am J Obstet Gynecol; 2021 Dec; 225(6):649.e1-649.e9. PubMed ID: 34256029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cervical cancer screening in Poland and worldwide].
    Spaczyński M; Nowak-Markwitz E; Kedzia W
    Ginekol Pol; 2007 May; 78(5):354-60. PubMed ID: 17867325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
    Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
    J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One Pap smear of benefit in developing countries.
    Bagchi S
    Lancet Oncol; 2005 Jan; 6(1):9. PubMed ID: 15672493
    [No Abstract]   [Full Text] [Related]  

  • 8. Epidemiology of preinvasive lesions.
    Surís JC; Dexeus S; López-Marín L
    Eur J Gynaecol Oncol; 1999; 20(4):302-5. PubMed ID: 10475128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Zealand's cervical cytology history: implications for the control of cervical cancer.
    Paul C
    N Z Med J; 2004 Nov; 117(1206):U1170. PubMed ID: 15570339
    [No Abstract]   [Full Text] [Related]  

  • 10. [The value of screening using cervicography in dysplasia and neoplasms of the uterine cervix].
    Coibion M; Guenier C; Miloiu A; Andry M; Bonnal JL; Nogaret JM
    Rev Med Brux; 1990; 11(1-2):16-20. PubMed ID: 2406832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer screening and updated Pap guidelines.
    Warren JB; Gullett H; King VJ
    Prim Care; 2009 Mar; 36(1):131-49, ix. PubMed ID: 19231606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do you still need a Pap test?
    Johns Hopkins Med Lett Health After 50; 2012 Feb; 23(12):6. PubMed ID: 22397002
    [No Abstract]   [Full Text] [Related]  

  • 13. When your patient asks: "Doctor, I read there have been serious Pap smear errors. Shouldn't I get one of those new computer Pap smears?".
    Boronow RC; Cavett JR
    J Miss State Med Assoc; 1998 Apr; 39(4):136-41. PubMed ID: 9585689
    [No Abstract]   [Full Text] [Related]  

  • 14. [Estimated results of prophylactic physical examinations detecting cervical cancer in Center of Oncology in Bydgoszcz in years 2001-2003].
    Mierzwa T; Grabiec M; Walentowicz M
    Ginekol Pol; 2005 Sep; 76(9):693-8. PubMed ID: 16417080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?
    Austin RM; Onisko A; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):602-606. PubMed ID: 32839150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methods of cervical cancer screening and facing new problems in China].
    Zhang WH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):881-4. PubMed ID: 19173985
    [No Abstract]   [Full Text] [Related]  

  • 17. Less frequent Pap smears for low-risk women?
    Sanders FN
    S Afr Med J; 2004 Jun; 94(6):435-6. PubMed ID: 15250453
    [No Abstract]   [Full Text] [Related]  

  • 18. Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia.
    Liao SY; Stanbridge EJ
    Cancer; 2000 Mar; 88(5):1108-21. PubMed ID: 10699902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for cervical cancer in criminal justice settings.
    Binswanger IA; Mueller S; Clark CB; Cropsey KL
    J Womens Health (Larchmt); 2011 Dec; 20(12):1839-45. PubMed ID: 22004180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.